KRAS and Patent ductus arteriosus: The activating mutation in KRAS then cooperates with the loss‐of‐function mutations of tumor suppressor genes, including TP53, SMAD4, and CKDN2A, to further promote PDA progression.[2] In contrast, recurrent genetic alterations driving PDA metastasis remain elusive.